Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8201800 | 0.92 | PPARA (0.51) | PPARAEPHX2LPAR1LPAR2LPAR3 | |
| SCHEMBL9351056 | 0.92 | PPARA (0.51) | PPARAEPHX2LPAR1LPAR2LPAR3 | |
| SCHEMBL28744093 | 0.92 | PPARA (0.51) | PPARAEPHX2LPAR1LPAR2LPAR3 | |
| Bromide SCHEMBL28559142 | 0.91 | PPARA (0.50) | PPARAEPHX2LPAR1LPAR2LPAR3 | |
| SCHEMBL16143788 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 | |
| SCHEMBL28554627 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 | |
| SCHEMBL466284 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 | |
| SCHEMBL10705860 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 | |
| SCHEMBL6027841 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 | |
| SCHEMBL18679474 | 0.88 | EPHX1 (0.46) | PPARAEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204344-A1 | PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES | B.G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204344-A1 | PROCESS FOR PREPARING CUBIC PI-PHASE MONOCHALCOGENIDES | KDR, HRH3, HRH4 | PPARA 494/4885EPHX2 1072/4885LPAR1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.